0.15Open0.15Pre Close0 Volume58 Open Interest68.00Strike Price0.00Turnover5546.65%IV13.00%PremiumNov 29, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.0512Delta0.0155Gamma519.93Leverage Ratio-382.3939Theta0.0000Rho-26.60Eff Leverage0.0001Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet